Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 19, 2008

TorreyPines Therapeutics Licenses Three Alzheimer’s Compounds to QR Pharma

  • TorreyPines Therapeutics licensed the worldwide rights to Posiphen™, bisnorcymcerine, and phenserineto QR Pharma. Under the terms of the agreement, TorreyPines will receive an annual license fee, clinical and regulatory milestone payments, sublicensing fees, and royalties on product sales. The agreement also provides QR Pharma with the right to acquire TorreyPines' ownership of the compounds.

    These three compounds, all targeted at Alzheimer’s Disease, originated at Axonyx, which was acquired by TorreyPines in 2006.

    "This is the latest in a series of agreements we have executed toward achieving our goal of monetizing noncore assets and becoming a development-only company. Our focus now clearly remains on advancing our clinical product candidates tezampanel, NGX426 and NGX267," said Ev Graham, CEO of TorreyPines.

    Earlier this month, TorreyPines sold its Alzheimer’s disease genetics research program to Eisai.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »